Get the Stockscreener App
38.84
7.26%
2.63
Monopar Therapeutics Inc stock is traded at $38.84, with a volume of 55,564.
It is up +7.26% in the last 24 hours and down -6.97% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$36.21
Open:
$36.85
24h Volume:
55,564
Relative Volume:
1.31
Market Cap:
$239.64M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-16.89
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
+7.71%
1M Performance:
-6.97%
6M Performance:
+22.52%
1Y Performance:
+1,492%
1-Day Range:
$35.01
$38.86
1-Week Range:
$32.77
$38.86
52-Week Range:
$2.2901
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
38.84 | 209.35M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
AlphaQuest LLC Makes New $44,000 Investment in Monopar Therapeutics Inc. $MNPR - Defense World
Is Monopar Therapeutics Inc. stock suitable for long term investing2025 EndofYear Setup & Short-Term Trading Alerts - khodrobank.com
Applying big data sentiment scoring on Monopar Therapeutics Inc.Portfolio Profit Report & Weekly Stock Performance Updates - Newser
Is Monopar Therapeutics Inc. currently under institutional pressureWeekly Trade Recap & High Conviction Buy Zone Picks - khodrobank.com
Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent (NASDAQ:MNPR) - Seeking Alpha
Is Monopar Therapeutics Inc.’s growth already priced inJuly 2025 Big Picture & AI Powered Buy and Sell Recommendations - khodrobank.com
Best data tools to analyze Monopar Therapeutics Inc. stock2025 Macro Impact & Free Accurate Trade Setup Notifications - Newser
Will Monopar Therapeutics Inc. bounce back from current supportWeekly Market Report & Low Volatility Stock Recommendations - Newser
Should you hold or exit Monopar Therapeutics Inc. nowLayoff News & AI Based Buy and Sell Signals - Newser
Visual analytics tools that track Monopar Therapeutics Inc. performanceWeekly Trade Review & Smart Investment Allocation Tips - Newser
Will Monopar Therapeutics Inc. outperform the marketGlobal Markets & Daily Technical Forecast Reports - Newser
How to escape a deep drawdown in Monopar Therapeutics Inc.Jobs Report & Accurate Technical Buy Alerts - Newser
Is Monopar Therapeutics Inc. stock showing strong momentumEarnings Miss & Reliable Intraday Trade Plans - khodrobank.com
Evaluating Monopar Therapeutics Inc. with trendline analysisWeekly Market Report & Weekly High Momentum Picks - Newser
Monopar a new outperform at Oppenheimer on Wilson disease candidate - Seeking Alpha
How moving averages guide Monopar Therapeutics Inc. tradingWeekly Gains Summary & High Conviction Trade Alerts - Newser
Will Monopar Therapeutics Inc. stock recover after earningsJuly 2025 Spike Watch & Weekly Watchlist of Top Performers - khodrobank.com
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting - The Manila Times
Monopar's Wilson Disease Drug Study Selected for ANA 2025 Meeting | MNPR Stock News - Stock Titan
Raymond James Initiates Monopar Therapeutics at Strong Buy With $80 Price Target - MarketScreener
Detecting price anomalies in Monopar Therapeutics Inc. with AIQuarterly Profit Review & Reliable Price Action Trade Plans - Newser
Will Monopar Therapeutics Inc. see short term momentum2025 Technical Patterns & Long-Term Safe Investment Plans - Newser
Risk vs reward if holding onto Monopar Therapeutics Inc.Portfolio Growth Summary & Intraday High Probability Setup Alerts - Newser
Sentiment analysis tools applied to Monopar Therapeutics Inc2025 Risk Factors & Technical Buy Zone Confirmations - Newser
Sentiment analysis tools applied to Monopar Therapeutics Inc.July 2025 Trends & Real-Time Chart Breakout Alerts - Newser
What analysts say about Monopar Therapeutics Inc. stockMarket Growth Report & Entry and Exit Point Strategies - khodrobank.com
Real time pattern detection on Monopar Therapeutics Inc. stockPortfolio Growth Summary & High Accuracy Trade Alerts - Newser
Statistical indicators supporting Monopar Therapeutics Inc.’s strengthStop Loss & Daily Stock Trend Reports - Newser
Published on: 2025-09-02 23:38:23 - Newser
Using data models to predict Monopar Therapeutics Inc. stock movementPortfolio Gains Summary & Smart Allocation Stock Reports - Newser
Visualizing Monopar Therapeutics Inc. stock with heatmaps2025 Bull vs Bear & Free Long-Term Investment Growth Plans - Newser
Published on: 2025-09-02 12:19:21 - Newser
Technical Charts Suggest Momentum Shift in Monopar Therapeutics Inc. getLinesFromResByArray error: size == 0 - thegnnews.com
Can Monopar Therapeutics Inc. outperform in the next rallyForecast Cut & Weekly Stock Breakout Alerts - khodrobank.com
Why Monopar Therapeutics Inc. is moving todayJuly 2025 Market Mood & Weekly Momentum Picks - Newser
Will Monopar Therapeutics Inc. price bounce be sustainableWeekly Trade Recap & High Return Trade Opportunity Guides - Newser
Is Monopar Therapeutics Inc. stock reversal real or fakeGap Up & Free Technical Confirmation Trade Alerts - Newser
Can machine learning forecast Monopar Therapeutics Inc. recoveryPortfolio Risk Report & Weekly High Potential Stock Alerts - Newser
Price Action Confirms Reversal in Monopar Therapeutics Inc. Trend getLinesFromResByArray error: size == 0 - kangso.co.kr
What’s the RSI of Monopar Therapeutics Inc. stockJuly 2025 Big Picture & AI Powered Market Trend Analysis - khodrobank.com
Monopar Therapeutics Inc. Reversal Rally May Surprise Bears getLinesFromResByArray error: size == 0 - 강소기업뉴스
Custom strategy builders for tracking Monopar Therapeutics Inc.CEO Change & AI Based Buy and Sell Signals - Newser
Monopar Therapeutics Inc. Stocks Attracting Dip Buyers getLinesFromResByArray error: size == 0 - thegnnews.com
Published on: 2025-08-31 12:56:46 - Newser
Using fundamentals and technicals on Monopar Therapeutics Inc.July 2025 Analyst Calls & Intraday High Probability Setup Alerts - Newser
Will Monopar Therapeutics Inc. stock go up soon2025 Sector Review & Technical Analysis for Trade Confirmation - Newser
What the charts say about Monopar Therapeutics Inc. todayWeekly Trade Report & AI Powered Buy/Sell Recommendations - Newser
Has Monopar Therapeutics Inc. found a price floorJuly 2025 Short Interest & Verified High Yield Trade Plans - Newser
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monopar Therapeutics Inc Stock (MNPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STARR CHRISTOPHER M | Director |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
5,173 |
| Robinson Chandler | Chief Executive Officer |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
73,472 |
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):